ReviewClinical interventions in aging2007
Vascular dementia: pharmacological treatment approaches and perspectives.
Review in Clinical interventions in aging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Effect of Water Temperature during Aquatic Exercise on Cognitive Impairment in Mice with Chronic Cerebral Hypoperfusion.Journal of vascular research · 2026Article
- Systemic Lupus Erythematosus With Catastrophic APS and Libman-Sacks Endocarditis in a Patient With Autoimmune Hemolytic Anemia: A Case Report.Clinical case reports · 2025Article
- Article
- Molecular Hydrogen Modulates T Cell Differentiation and Enhances Neuro-Regeneration in a Vascular Dementia Mouse Model.Antioxidants (Basel, Switzerland) · 2025Article
- Single-nucleus RNA sequencing of human periventricular white matter in vascular dementia.bioRxiv : the preprint server for biology · 2024Article
- Methanol extract ofFrontiers in pharmacology · 2024Article
- Preliminary MRS study of critical values of relevant brain metabolites in elderly Chinese patients with post-stroke cognitive impairment.IBRO neuroscience reports · 2023Article
- Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Article
- Review
- A Comprehensive Survey on the Detection, Classification, and Challenges of Neurological Disorders.Biology · 2022Review
- Deciphering the role of PGC-1α in neurological disorders: from mitochondrial dysfunction to synaptic failure.Neural regeneration research · 2022Review
- Construction of an efficientFrontiers in bioengineering and biotechnology · 2022Article
- VEGF Modulates the Neural Dynamics of Hippocampal Subregions in Chronic Global Cerebral Ischemia Rats.Neuromolecular medicine · 2021Article
- A Baeyer-Villiger Monooxygenase Gene Involved in the Synthesis of Lysergic Acid Amides Affects the Interaction of the Fungus Metarhizium brunneum with Insects.Applied and environmental microbiology · 2021Article
- Mild Cognitive Impairment and Mild Dementia: The Role ofPharmaceuticals (Basel, Switzerland) · 2021Review
- Vascular Dementia and Underlying Sex Differences.Frontiers in aging neuroscience · 2021Review
- Potential of PET/CT in assessing dementias with emphasis on cerebrovascular disorders.European journal of nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular dementia is a common condition for which there are no effective approved pharmacological treatments available. Absence of effective treatments creates a difficult situation for those suffering from the disease, their caregivers, and healthcare providers. This review will address our current understanding of the mechanisms of nerve cell damage due to ischemia and summarize available clinical trial data on several commonly used compounds including memantine, donepezil, galantamine, rivastigmine, nimodipine, hydergine, nicergoline, CDP-choline, folic acid, as well as such nonpharmacological approaches as validation therapy.
Indexed as
Identifiers
18044183PMC2685259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.